mVASC®
Repair, reconstruction, replacement, or supplementation of damaged ECM in skin defects extending into the hypodermis
Key Facts
About Microvascular Tissues
Microvascular Tissues is a commercial-stage biotech company that has developed mVASC®, a unique extracellular matrix product derived from human cadaveric microvascular tissues. The product is designed as an off-the-shelf graft for repairing complex skin wounds that extend into the hypodermis, aiming to leverage the inherent structural and biological properties of native ECM to promote healing. Spun out from Tornier, Inc. (now Stryker) in 2014/2015, the company is privately held and has advanced its lead product to market. Its strategy focuses on addressing vascular deficiencies in wound care, a niche with significant unmet need in chronic and surgical wounds.
View full company profile